163 related articles for article (PubMed ID: 32779300)
1. Shikonin is a novel and selective IMPDH2 inhibitor that target triple-negative breast cancer.
Wang W; Wu Y; Chen S; Liu X; He J; Wang S; Lu W; Tang Y; Huang J
Phytother Res; 2021 Jan; 35(1):463-476. PubMed ID: 32779300
[TBL] [Abstract][Full Text] [Related]
2. Shikonin inhibits triple-negative breast cancer-cell metastasis by reversing the epithelial-to-mesenchymal transition via glycogen synthase kinase 3β-regulated suppression of β-catenin signaling.
Chen Y; Chen ZY; Chen L; Zhang JY; Fu LY; Tao L; Zhang Y; Hu XX; Shen XC
Biochem Pharmacol; 2019 Aug; 166():33-45. PubMed ID: 31071331
[TBL] [Abstract][Full Text] [Related]
3. A modified natural small molecule inhibits triple-negative breast cancer growth by interacting with Tubb3.
Han H; Yang M; Wen Z; Wang X; Lai X; Zhang Y; Fang R; Yin T; Yang X; Wang X; Zhao Q; Qi J; Chen H; Lin H; Yang Y
Phytomedicine; 2024 Apr; 126():154894. PubMed ID: 38377719
[TBL] [Abstract][Full Text] [Related]
4. Combination Treatment Using Pyruvate Kinase M2 Inhibitors for the Sensitization of High Density Triple-negative Breast Cancer Cells.
Lee JS; Oh Y; Lee JS; Park JH; Shin JK; Han JH; Kim HS; Yoon S
In Vivo; 2022; 36(5):2105-2115. PubMed ID: 36099094
[TBL] [Abstract][Full Text] [Related]
5. RIP1K and RIP3K provoked by shikonin induce cell cycle arrest in the triple negative breast cancer cell line, MDA-MB-468: necroptosis as a desperate programmed suicide pathway.
Shahsavari Z; Karami-Tehrani F; Salami S; Ghasemzadeh M
Tumour Biol; 2016 Apr; 37(4):4479-91. PubMed ID: 26496737
[TBL] [Abstract][Full Text] [Related]
6. Shikonin, a constituent of Lithospermum erythrorhizon exhibits anti-allergic effects by suppressing orphan nuclear receptor Nr4a family gene expression as a new prototype of calcineurin inhibitors in mast cells.
Wang X; Hayashi S; Umezaki M; Yamamoto T; Kageyama-Yahara N; Kondo T; Kadowaki M
Chem Biol Interact; 2014 Dec; 224():117-27. PubMed ID: 25451590
[TBL] [Abstract][Full Text] [Related]
7. Shikonin, an ingredient of Lithospermum erythrorhizon, down-regulates the expression of steroid sulfatase genes in breast cancer cells.
Zhang Y; Qian RQ; Li PP
Cancer Lett; 2009 Oct; 284(1):47-54. PubMed ID: 19419812
[TBL] [Abstract][Full Text] [Related]
8. Berberrubine is a novel and selective IMPDH2 inhibitor that impairs the growth of colorectal cancer.
He X; Cui J; Ma H; Abuduaini N; Huang Y; Tang L; Wang W; Zhang Y; Wang Y; Lu W; Feng B; Huang J
Biochem Pharmacol; 2023 Dec; 218():115868. PubMed ID: 37871880
[TBL] [Abstract][Full Text] [Related]
9. Myricetin is a novel inhibitor of human inosine 5'-monophosphate dehydrogenase with anti-leukemia activity.
Pan H; Hu Q; Wang J; Liu Z; Wu D; Lu W; Huang J
Biochem Biophys Res Commun; 2016 Sep; 477(4):915-922. PubMed ID: 27378425
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of inosine 5'-monophosphate dehydrogenase type II mediates chemoresistance to human osteosarcoma cells.
Fellenberg J; Kunz P; Sähr H; Depeweg D
PLoS One; 2010 Aug; 5(8):e12179. PubMed ID: 20808934
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic cooperation between auranofin, a thioredoxin reductase inhibitor and anti-PD-L1 antibody for treatment of triple-negative breast cancer.
Raninga PV; Lee AC; Sinha D; Shih YY; Mittal D; Makhale A; Bain AL; Nanayakarra D; Tonissen KF; Kalimutho M; Khanna KK
Int J Cancer; 2020 Jan; 146(1):123-136. PubMed ID: 31090219
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and validation of novel nitrogen-based chalcone analogs against triple negative breast cancer.
Elkhalifa D; Siddique AB; Qusa M; Cyprian FS; El Sayed K; Alali F; Al Moustafa AE; Khalil A
Eur J Med Chem; 2020 Feb; 187():111954. PubMed ID: 31838326
[TBL] [Abstract][Full Text] [Related]
13. A novel orally available seleno-purine molecule suppresses triple-negative breast cancer cell proliferation and progression to metastasis by inducing cytostatic autophagy.
Chang CH; Bijian K; Wernic D; Su J; da Silva SD; Yu H; Qiu D; Asslan M; Alaoui-Jamali MA
Autophagy; 2019 Aug; 15(8):1376-1390. PubMed ID: 30773992
[TBL] [Abstract][Full Text] [Related]
14. Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer.
Lee J; Lim B; Pearson T; Choi K; Fuson JA; Bartholomeusz C; Paradiso LJ; Myers T; Tripathy D; Ueno NT
Breast Cancer Res Treat; 2019 Jun; 175(2):339-351. PubMed ID: 30826934
[TBL] [Abstract][Full Text] [Related]
15. Monoamine oxidase inhibitory naphthoquinones from the roots of Lithospermum erythrorhizon.
Choi WH; Hong SS; Lee SA; Han XH; Lee KS; Lee MK; Hwang BY; Ro JS
Arch Pharm Res; 2005 Apr; 28(4):400-4. PubMed ID: 15918512
[TBL] [Abstract][Full Text] [Related]
16. Novel shikonin derivatives suppress cell proliferation, migration and induce apoptosis in human triple-negative breast cancer cells via regulating PDK1/PDHC axis.
Chen Q; Han H; Lin F; Yang L; Feng L; Lai X; Wen Z; Yang M; Wang C; Ma Y; Yin T; Lu G; Lin H; Qi J; Yang Y
Life Sci; 2022 Dec; 310():121077. PubMed ID: 36244412
[TBL] [Abstract][Full Text] [Related]
17. Natural Compound Shikonin Is a Novel PAK1 Inhibitor and Enhances Efficacy of Chemotherapy against Pancreatic Cancer Cells.
Ji W; Sun X; Gao Y; Lu M; Zhu L; Wang D; Hu C; Chen J; Cao P
Molecules; 2022 Apr; 27(9):. PubMed ID: 35566098
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer.
Granados-Principal S; Liu Y; Guevara ML; Blanco E; Choi DS; Qian W; Patel T; Rodriguez AA; Cusimano J; Weiss HL; Zhao H; Landis MD; Dave B; Gross SS; Chang JC
Breast Cancer Res; 2015 Feb; 17(1):25. PubMed ID: 25849745
[TBL] [Abstract][Full Text] [Related]
19. Human ACAT inhibitory effects of shikonin derivatives from Lithospermum erythrorhizon.
An S; Park YD; Paik YK; Jeong TS; Lee WS
Bioorg Med Chem Lett; 2007 Feb; 17(4):1112-6. PubMed ID: 17157006
[TBL] [Abstract][Full Text] [Related]
20. The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.
Vázquez R; Riveiro ME; Astorgues-Xerri L; Odore E; Rezai K; Erba E; Panini N; Rinaldi A; Kwee I; Beltrame L; Bekradda M; Cvitkovic E; Bertoni F; Frapolli R; D'Incalci M
Oncotarget; 2017 Jan; 8(5):7598-7613. PubMed ID: 27935867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
